VISTIDE: CIDOFOVIR,INJECTION.
The CIDOFOVIR,INJECTION is a the manufacturer industrial component. Key specifications include end_item_identification: FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYDROME (AIDS), part_name_assigned_by_controlling_agency: CIDOFOVIR INJECTION 375MG ANHYDROUS 5ML AQUEOUS CONCENTRATION 75MG/MLVIAL, american_hospital_formulary_service_classification_number: 081800. This part is cataloged in the U.S.
Government catalog under NSN 6505-01-501-0628, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| end_item_identification | FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYDROME (AIDS) |
| part_name_assigned_by_controlling_agency | CIDOFOVIR INJECTION 375MG ANHYDROUS 5ML AQUEOUS CONCENTRATION 75MG/MLVIAL |
| american_hospital_formulary_service_classification_number | 081800 |
| NSN | 6505-01-501-0628 |
| SPECIAL FEATURES | SUPPLIED IN A CLEAR GLASS VIAL, EACH CONTAINING 375 MG OF ANHYDROUS CIDOFOVIR IN 5 ML AQUEOUS SOLUTION AT A CONCENTRAION OF 75 MG/ML; STERILE; SINGLE DOSE VIAL; PRESERVATIVE FREE; INTRAVENOUS USE ONLY; STORE AT CONTROLLED ROOM TEMPERATURE 20 TO 25 DEGREE C (68 TO 77 DEGREES F) |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | CIDOFOVIR INJECTION 375MG ANHYDROUS 5ML AQUEOUS CONCENTRATION 75MG/MLVIAL |
| END ITEM IDENTIFICATION | FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYDROME (AIDS) |
| AMERICAN HOSPITAL FORMULARY SERVICE CLASSIFICATION NUMBER | 081800 |